Elverdin J C, Luchelli-Fortis M A, Stefano F J, Perec C J
J Pharmacol Exp Ther. 1984 Apr;229(1):261-6.
The alpha adrenoceptor that mediates the secretory responses to norepinephrine in submaxillary glands was characterized. All three alpha antagonists employed produced in innervated glands parallel displacements of the dose-response curves to norepinephrine, prazosin being 30 and 100 times more potent than phentolamine and yohimbine, respectively. Chronic sympathetic denervation produced supersensitivity to norepinephrine. Under these conditions prazosin also was more potent than yohimbine but the shifts of the dose-response curves to norepinephrine were nonparallel. Potentiation of norepinephrine by cocaine did not modify the effects of prazosin in innervated glands. The nonparallel displacements observed in denervated glands were related to the development of postjunctional supersensitivity of the beta adrenoceptor-mediated responses because after administration of propranolol the displacements produced by prazosin were parallel. Responses to methoxamine were not potentiated by denervation and were competitively antagonized by prazosin in both innervated and denervated glands. Specific [3H]clonidine binding to membranes of submaxillary glands showed at least two independent sites with a KD1 of 0.37 nM and a KD2 of 65 nM. The number of sites of each component was doubled after chronic sympathetic denervation. Binding of [3H]prazosin (KD, 0.43 nM; maximum binding sites, 78.5 fmol/mg of protein) was not affected by denervation. The present findings show that sialagogue responses to sympathomimetic agents are mediated by alpha-1 adrenoceptor activation in both innervated and denervated submaxillary glands. Chronic sympathetic denervation does not produce postjunctional supersensitivity of the alpha-1-mediated responses and the supersensitivity of the beta-mediated responses interferes with determinations of dose-response curves to the sympathetic neurotransmitter.
对介导颌下腺对去甲肾上腺素分泌反应的α肾上腺素能受体进行了特性分析。所使用的三种α拮抗剂在神经支配的腺体中均使去甲肾上腺素的剂量-反应曲线产生平行位移,哌唑嗪的效力分别比酚妥拉明和育亨宾强30倍和100倍。慢性交感神经去神经支配导致对去甲肾上腺素超敏。在这些条件下,哌唑嗪也比育亨宾更有效,但去甲肾上腺素的剂量-反应曲线位移不平行。可卡因对去甲肾上腺素的增强作用并未改变哌唑嗪在神经支配腺体中的作用。在去神经支配的腺体中观察到的不平行位移与β肾上腺素能受体介导反应的节后超敏的发展有关,因为在给予普萘洛尔后,哌唑嗪产生的位移是平行的。对甲氧明的反应在去神经支配后未增强,并且在神经支配和去神经支配的腺体中均被哌唑嗪竞争性拮抗。特异性[3H]可乐定与颌下腺膜的结合显示至少有两个独立位点,KD1为0.37 nM,KD2为65 nM。慢性交感神经去神经支配后,每个组分的位点数量增加一倍。[3H]哌唑嗪(KD,0.43 nM;最大结合位点,78.5 fmol/mg蛋白质)的结合不受去神经支配的影响。目前的研究结果表明,在神经支配和去神经支配的颌下腺中,拟交感神经药的催涎反应均由α-1肾上腺素能受体激活介导。慢性交感神经去神经支配不会产生α-1介导反应的节后超敏,而β介导反应的超敏会干扰对交感神经递质剂量-反应曲线的测定。